Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MD1003 cardiac repolarization study
NCT04168723Phase 1Unknown
- Sponsor
- MedDay Pharmaceuticals
- Start
- Nov 2019
- Primary completion
- Mar 2020
- Modality
- Orthosteric Ligands, Metabolically Activated Prodrugs
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of biotin in multiple sclerosis (MS) (3 arms), sponsored by MedDay Pharmaceuticals. Primary endpoint: Change from baseline QTcF at Day 8. Status: unknown.
02
Drugs
biotin
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on NCT04168723.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04168723.